AbbVie vs Merck & Company at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | ABBV | MRK |
|---|---|---|
| Market cap | $457.23B | $378.46B |
| Price | $258.15 | $149.54 |
| P/E ratio (TTM) | 95.29 | 14.18 |
| P/B ratio (MRQ) | 0 | 4.92 |
| P/S ratio (TTM) | 6.58 | 3.98 |
| Revenue growth (1Y) | 8.57% | 1.31% |
| Return on equity (TTM) | -129.24% | 34.70% |
| Return on invested capital (TTM) | 21.13% | 22.71% |
| Gross margin (TTM) | 73.70% | 82.44% |
| Net margin (TTM) | 5.79% | 13.59% |
| Dividend yield (TTM) | 2.68% | 2.22% |
How they differ
AbbVie is the larger company at $457.23B versus $378.46B, making them close in size.
On trailing earnings, Merck & Company is the cheaper of the two at 14.18 against 95.29 for AbbVie.
On sales, Merck & Company is the cheaper of the two at 3.98 against 6.58 for AbbVie.
AbbVie leads on revenue growth over the past year, 8.57% against 1.31%.
Merck & Company leads on return on invested capital, 22.71% against 21.13%.
Merck & Company leads on gross margin, 82.44% against 73.70%.
AbbVie offers the higher yield at 2.68% against 2.22%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving AbbVie or Merck & Company.